

COMPANY PROFILE FORM	
Name	<b>Biovista</b>
Short profile	<p>Biovista is a drug repositioning company established in 1993 with offices in Charlottesville VA, USA and Athens, Greece. Biovista's repositioning programs leverage the company's technology platform to identify suitable drugs and reposition them in isolation or in combination with other drugs to therapeutic areas that are currently not covered by existing products.</p> <p>By selecting drugs that already satisfy basic toxicity, ADME and related criteria, Biovista is able to deliver significant value at reduced cost and in dramatically shorter time frames than is normally the case. Biovista's technology not only repositions drugs but also de-risks them, by profiling potential adverse events before these happen. Therefore the technology together with the benefit, addresses the risk side of the equation, namely the adverse effects profile, making for much more balanced predictions of the clinical outcome of the repositioned drug.</p> <p>The company has initiated its own drug repositioning efforts in several conditions, where the drugs profiled and screened meet two major criteria:</p> <ul style="list-style-type: none"> <li>• they display significant biological plausibility as potential therapies for the new indications and</li> <li>• there is no prior art in the patent or scientific literature linking them to the new indications.</li> </ul> <p>In addition, drugs are screened for at least equivalent efficacy with current standards of treatment, and with equal or lower risk profiles.</p> <p>Biovista products are developed using its proprietary Discovery Algorithmics™ platform. Discovery Algorithmics™ is running off one of the world's largest MySQL databases. Currently at over 4 billion rows and 17 million records, this resource supports the company's own repositioning program as well as diverse client projects ranging from AE profiling to clinical hold situations.</p> <p>The company has an active R&amp;D program that aims to deliver high value treatments as well as tools and services in support of the life sciences industry. Biovista's current repositioning program is focused on CNS and eye disorders with additional therapeutic areas being added in Q2 of 2009. Since September 2008 Biovista has submitted 5 patent applications on 12 drugs, in multiple sclerosis (MS), epilepsy and macular degeneration (AMD). BVA-101 recently showed statistically significant efficacy in animal models of MS. Animal model trials on additional Biovista drugs in the other indications are ongoing, for BVA-101 also in epilepsy, BVA-201 in MS, and BVA-301 in AMD. The company is currently running efficacy experiments for all its repositioning programs.</p> <p>Biovista's network of clients and collaborators includes large biotech and pharma companies as well as top-tier universities in the US and Europe. Biovista's clients include: Millipore, Promega, Wyeth, Qiagen, Biogen Idec, Novo Nordisk, Novus Biosciences, Cempra, Harvard University, University of Pennsylvania, UC Davis and University Hospital of the Saarland. Collaborators within EU projects include Unilever, France Telecom, EBI, IBM, EMBL, Fraunhofer-IPSI, Universities of Liverpool, Geneva, UPM, Manchester, Innsbruck and others.</p>
Research and Development Activity:	<ol style="list-style-type: none"> <li>1 Drug repositioning in a variety of TAs</li> <li>2 Animal model testing (via CROs)</li> <li>3. Proof of Concept (PoC) Clinical Trials (CTs) in selected TAs</li> </ol> <p>To a lesser degree we are also interested in enhancements to our technology platform including (gene name disambiguation, information extraction etc)</p>
Partner search with activity in the following research areas:	<ol style="list-style-type: none"> <li>1. Animal model tests</li> <li>2. bioassays, RNA, histology</li> <li>3. other in vitro and in vivo experiments</li> </ol> <p>In all cases the results are confidential and unless otherwise agreed, the IP must rest with Biovista</p> <p>Main therapeutic areas of interest are CNS, Oncology and auto-immune diseases.</p>
CONTACT	
Name of Contact person:	Andreas Persidis
e-mail:	andreasp@biovista.com
Web Site:	www.biovista.com

